Echo Biotech

Established in 2017 and headquartered in Beijing, China, Echo Biotech engages in exosome research, clinical transformation and regenerative medicine development. The company collaborates with more than 100 hospitals across China and has jointly published over 100 peer-reviewed papers, including more than 60 exosome-related research articles. Echo Biotech holds over 10 patents related to exosome technology and has built a comprehensive R&D and GMP production system. In November 2025, the company raised approximately CNY 100 million in Series B funding led by returning investor Zbjl Capital, with participation from new investor BIO-TOWN Capital.

The company's main business is divided into two parts: one is the research and development of innovative drugs based on exosomes, which mainly cover the fields of tumor immunity, rare diseases and neurological diseases. The second is translational medicine research services based on exosomes, including body fluid exosomes, tissue exosomes, exosomal functions, and single-cell joint tissue exosomes overall solutions, mainly in cooperation with clinical experts to carry out scientific research. The company generates revenue through R&D collaboration agreements, licensing of exosome technologies and the provision of translational medicine research services to hospitals, universities, and pharmaceutical partners. The company will use the series B funding to advance the development of exosome-based regenerative therapies and drug-delivery technologies, improve production processes and quality systems, and accelerate the clinical and industrial application of its core pipelines.